10x Genomics introduced Atera, a new spatial biology platform that enables whole-transcriptome analysis with single-cell sensitivity at an unprecedented scale. This technology overcomes previous limitations by allowing comprehensive spatial studies on both fresh-frozen and FFPE tissues, aiding research in disease mechanisms and drug development. Early data from leading institutions, including the University of Pennsylvania and German Cancer Research Center, demonstrate Atera's ability to reveal complex tumor environments and immune interactions. The platform will be commercially available in late 2026, supported by a new cloud analysis system and service access to broaden research capabilities.
10x Genomics, a leader in life science technology, will announce its financial results for Q2 ended June 30, 2026, after market close on August 6, 2026. The company will hold a public conference call and live webcast at 1:30 p.m. PT to discuss its ea...
Torex Gold Resources announced positive drilling outcomes at its Morelos Complex, including the ELG Underground and Media Luna Cluster, indicating potential for significant resource expansion and extended mine life. High-grade mineralization was enco...
